Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum
Alternative Names: APL-2; Aspaveli; EMPAVELI; Pegcetacoplan injection - Apellis Pharmaceuticals/Swedish Orphan Biovitrum; SYFOVRELatest Information Update: 03 Jul 2024
At a glance
- Originator Apellis Pharmaceuticals
- Developer Apellis Pharmaceuticals; Swedish Orphan Biovitrum
- Class Anti-inflammatories; Anti-ischaemics; Antianaemics; Antithrombotics; Cyclic peptides; Eye disorder therapies; Polyethylene glycols; Urologics
- Mechanism of Action Complement C3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Age-related macular degeneration; Paroxysmal nocturnal haemoglobinuria
- Phase III Membranoproliferative glomerulonephritis
- Phase II Glomerulonephritis; IgA nephropathy; Lupus nephritis; Membranous glomerulonephritis; Thrombotic microangiopathy
- Phase I/II Wet age-related macular degeneration
- Discontinued Amyotrophic lateral sclerosis; Autoimmune haemolytic anaemia; Ischaemia
Most Recent Events
- 28 Jun 2024 Apellis plans to seek re-examination and expects a final opinion for pegcetacoplan for age-related macular degeneration from the Committee for Medicinal Products for Human Use (CHMP) in the fourth quarter of 2024
- 28 Jun 2024 Apellis receives negative opinion for pegcetacoplan for age-related macular degeneration from the Committee for Medicinal Products for Human Use (CHMP) in EU
- 10 Jun 2024 Updated fficacy data from phase III GALE extension trial in Age-related macular degeneration released by Apellis Pharmaceuticals